Trial Profile
A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Central pain; Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 05 Nov 2010 New trial record.